A Sad Message From Our Team. Loss of Our Co-founder Dr. Manfred Schmidt Read more
2020
GeneWerk secured a growth equity investment from Ampersand Capital Partners and established its US entity.
2014
GeneWerk GmbH was founded in July 2014 by Prof. Dr. Christof von Kalle, Dr. Manfred Schmidt and Dr. Annette Deichmann.
2013
GeneWerk’s founding team was involved in the safety assessment of Glybera, the first approved gene therapy drug in a western country.
2010
Gene therapy safety testing fee-for-service initiated at the German Cancer Research Center (DKFZ), Heidelberg, Germany.
2001
GeneWerk’s founding team was involved in the identification of retroviral integration-related serious adverse events (SAEs) in X-linked severe combined immunodeficiency (X-SCID) patients.
1998
LAM-PCR, the then gold standard for vector integration site analysis developed by Dr. Manfred Schmidt, was used in the first Europe-wide gene marking trial in Chronic Myelogenous Leukemia (CML) patients.
Want to get in touch?
Consult with our experts about solutions to your biosafety challenges.